MedPlus Health Services Ltd. (IN:MEDPLUS)
:MEDPLUS
Want to see IN:MEDPLUS full AI Analyst Report?
Top Page
MedPlus Health Services Ltd.
(MEDPLUS)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹956.00
▲(18.20% Upside)
Action:Reiterated
Date:05/23/26
The score is driven mainly by improving financial performance (growth with better recent cash flow) but is held back by thin/volatile margins and rising leverage. Technicals add support due to a clear uptrend, while the overall score is capped by a high P/E and lack of dividend yield data.
Positive Factors
Omnichannel retail model
MedPlus's omnichannel network of neighborhood pharmacies plus digital ordering and home delivery creates durable customer convenience and loyalty. This distribution breadth supports recurring prescription volumes, cross-selling of OTC/wellness items, and logistics scale that underpin steady revenue and competitive positioning over 2–6 months and beyond.
Negative Factors
Thin and volatile margins
Sustained net margins of roughly 1–3% and a sharp 2026 gross margin decline materially limit the firm's ability to convert sales into durable profits. Such a low-margin profile reduces buffers against cost inflation or competitive pricing, making long-term earnings and investment plans more sensitive to external shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Omnichannel retail model
MedPlus's omnichannel network of neighborhood pharmacies plus digital ordering and home delivery creates durable customer convenience and loyalty. This distribution breadth supports recurring prescription volumes, cross-selling of OTC/wellness items, and logistics scale that underpin steady revenue and competitive positioning over 2–6 months and beyond.
Read all positive factors
MedPlus Health Services Ltd. (MEDPLUS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹114.61B
Dividend YieldN/A
Average Volume (3M)39.52K
Price to Earnings (P/E)45.8
Beta (1Y)0.41
Revenue Growth12.33%
EPS Growth45.71%
CountryIN
Employees23,415
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)16.33
Shares Outstanding120,054,640
10 Day Avg. Volume11,750
30 Day Avg. Volume39,524
Financial Highlights & Ratios
PEG Ratio1.00
Price to Book (P/B)5.10
Price to Sales (P/S)1.46
P/FCF Ratio24.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.63
Revenue Forecast (FY)₹78.02B
MedPlus Health Services Ltd. Business Overview & Revenue Model
Company Description
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It offers pharmaceutical and wellness products, including medicines, vitamins, medical devices, and test kits; fast-moving consumer goods, such ...
How the Company Makes Money
MedPlus primarily makes money by selling pharmaceutical and health products to consumers through its network of retail pharmacies and its online/omnichannel channels. The core revenue stream is product sales—especially prescription medicines—suppl...
MedPlus Health Services Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
67
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.93B | 68.92B | 61.36B | 56.25B | 45.58B | 37.79B |
| Gross Profit | 13.27B | 6.40B | 14.70B | 12.14B | 9.82B | 7.85B |
| EBITDA | 4.41B | 6.07B | 3.24B | 2.08B | 1.41B | 1.87B |
| Net Income | 1.95B | 2.20B | 1.50B | 654.73M | 497.63M | 958.02M |
Balance Sheet | ||||||
| Total Assets | 35.72B | 39.33B | 33.60B | 30.05B | 27.97B | 25.94B |
| Cash, Cash Equivalents and Short-Term Investments | 5.02B | 4.62B | 4.40B | 1.65B | 2.89B | 6.58B |
| Total Debt | 22.04B | 14.24B | 11.20B | 10.10B | 9.05B | 8.15B |
| Total Liabilities | 17.28B | 19.58B | 16.20B | 14.27B | 13.06B | 11.77B |
| Stockholders Equity | 18.45B | 19.75B | 17.41B | 15.78B | 14.91B | 14.18B |
Cash Flow | ||||||
| Free Cash Flow | 2.71B | 4.04B | 4.95B | 593.38M | -785.95M | 521.68M |
| Operating Cash Flow | 3.13B | 5.27B | 5.54B | 1.44B | 904.10M | 1.70B |
| Investing Cash Flow | -680.55M | -1.59B | -3.32B | -827.99M | 4.29B | -7.03B |
| Financing Cash Flow | -1.22B | -2.55B | -2.28B | -1.98B | -1.70B | 4.40B |
MedPlus Health Services Ltd. Technical Analysis
Positive
808.80
Price Trends
864.86
Positive
846.94
Positive
827.43
Positive
Market Momentum
19.19
Negative
65.61
Neutral
58.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDPLUS, the sentiment is Positive. The current price of 808.8 is below the 20-day moving average (MA) of 896.00, below the 50-day MA of 864.86, and below the 200-day MA of 827.43, indicating a bullish trend. The MACD of 19.19 indicates Negative momentum. The RSI at 65.61 is Neutral, neither overbought nor oversold. The STOCH value of 58.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MEDPLUS.
MedPlus Health Services Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹281.63B | 41.73 | ― | 0.89% | 12.25% | 3.57% | |
73 Outperform | ₹74.76B | 34.04 | ― | 0.68% | 20.61% | 78.25% | |
72 Outperform | ₹109.54B | 44.11 | ― | 0.21% | 23.64% | 29.96% | |
63 Neutral | ₹114.61B | 45.82 | ― | ― | 12.33% | 45.71% | |
58 Neutral | ₹18.33B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹9.10B | 207.74 | ― | ― | 9.12% | ― |
* Healthcare Sector Average
IN:MEDPLUS
MedPlus Health Services Ltd.
897.60
-79.40
-8.13%
IN:KRSNAA
Krsnaa Diagnostics Limited
562.00
-80.19
-12.49%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,627.05
207.81
14.64%
IN:METROPOLIS
Metropolis Healthcare Ltd.
518.80
105.61
25.56%
IN:SASTASUNDR
Sastasundar Ventures Limited
303.95
32.65
12.03%
IN:THYROCARE
Thyrocare Technologies Ltd
466.35
135.02
40.75%
MedPlus Health Services Ltd. Corporate Events
MedPlus unit faces three-day drug license suspension at Telangana store
Mar 29, 2026
MedPlus Health Services Ltd., through its subsidiary Optival Health Solutions Private Limited, has disclosed that one of its drugstore licenses in Telangana has been suspended for three days by the Assistant Director, Drugs Control Administration,...
MedPlus subsidiary faces brief drug license suspension at Karnataka store
Mar 28, 2026
MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, received a three-day suspension of the drug license for one retail pharmacy in Kalyan Nagar, Dharwad, Karnataka. The order was issued by t...
MedPlus Subsidiary Faces Seven-Day Drug License Suspension at Andhra Pradesh Store
Mar 21, 2026
MedPlus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, received a seven-day suspension of a drug license for one pharmacy located on Bhimavaram P P Road in Andhra Pradesh. The suspension order was issu...
MedPlus Subsidiary Faces Two-Day Drug License Suspension at Karnataka Store
Mar 15, 2026
MedPlus Health Services Ltd. disclosed that its subsidiary, Optival Health Solutions, has received a two-day suspension of a drug license for one of its stores located at Bidadi Bus Stand in Karnataka. The suspension was ordered by the Assistant D...
MedPlus unit faces one-day drug license suspension at Telangana store
Feb 28, 2026
MedPlus Health Services Ltd. has disclosed that its subsidiary, Optival Health Solutions Private Limited, received a one-day suspension of the drug license for a pharmacy located in Kuntloor, Telangana. The suspension was ordered by the Assistant ...
MedPlus Schedules Virtual Investor Meet, Reaffirms Compliance on Disclosures
Feb 27, 2026
MedPlus Health Services Ltd. has announced that its key managerial personnel will participate in a sector-specific conference organized by Nirmal Bang on March 6, 2026, via a virtual meeting. The company clarified that no unpublished price-sensiti...
MedPlus Seeks Shareholder Nod for Material Related-Party Deal via E-Vote
Feb 24, 2026
MedPlus Health Services has initiated a postal ballot process to seek shareholder approval for material related party transactions with its material subsidiary, Optival Health Solutions Private Ltd. The company is conducting the vote exclusively t...
MedPlus Subsidiary Faces Three-Day Drug License Suspension at Telangana Store
Feb 23, 2026
MedPlus Health Services Ltd. disclosed that its subsidiary Optival Health Solutions Private Limited has received a three-day suspension of a drug license for one pharmacy located at Surya Nagar Colony, Mallpur in Telangana, ordered by the Assistan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.